NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.
Philips FetView will offer real-time, off cart remote patient management with access to data from any ultrasound system
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Subscribe To Our Newsletter & Stay Updated
